Skip to content

Study · Animal study (in vivo) · 2019

7 results

Thymosin Alpha-1 Inhibits Complete Freund's Adjuvant-Induced Pain and Production of Microglia-Mediated Pro-inflammatory Cytokines in Spinal Cord.

Xu Y, Jiang Y, Wang L, Huang J, Wen J, Lv H, Wu X, Wan C, Yu C, Zhang W, Zhao J, Zhou Y, Chen Y

Neuroscience bulletin21 Feb 2019Cited by 27 (Europe PMC)

PMID30790216 (opens in a new tab)PMCIDPMC6616621 (opens in a new tab)DOI10.1007/s12264-019-00346-z (opens in a new tab)PepBankPUB-30790216
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In animals with CFA-induced inflammatory pain, intraperitoneal thymosin alpha‑1 attenuated pain hypersensitivity.

    In plain wordsIn animals with inflammatory pain, thymosin alpha‑1 injection lowered pain sensitivity.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCFA-induced pain hypersensitivity
    Study

    n: not reported in source

    CFA-induced inflammatory pain
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study.

    Source sentences

    Summary
    intraperitoneal injection of Tα1 attenuated complete Freund's adjuvant (CFA)-induced pain hypersensitivity
  2. 02AnimalAnimal study (in vivo)Mechanism

    In animals with CFA-induced inflammatory pain, thymosin alpha‑1 decreased up-regulation of TNF-α in inflamed skin and spinal cord.

    In plain wordsIn animals with inflammatory pain, thymosin alpha‑1 lowered the inflammation marker TNF-α in skin and spinal cord.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTNF-α in inflamed skin and spinal cord
    Study

    n: not reported in source

    CFA-induced inflammatory pain
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · intraperitonealAs given in this study.

    Source sentences

    Summary
    decreased the up-regulation of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) in inflamed skin and the spinal cord
  3. 03AnimalAnimal study (in vivo)Mechanism

    In animals with CFA-induced inflammatory pain, thymosin alpha‑1 decreased up-regulation of IL-1β in inflamed skin and spinal cord.

    In plain wordsIn animals with inflammatory pain, thymosin alpha‑1 lowered the inflammation marker IL-1β in skin and spinal cord.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-1β in inflamed skin and spinal cord
    Study

    n: not reported in source

    CFA-induced inflammatory pain
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · intraperitonealAs given in this study.

    Source sentences

    Summary
    decreased the up-regulation of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) in inflamed skin and the spinal cord
  4. 04AnimalAnimal study (in vivo)Mechanism

    In animals with CFA-induced inflammatory pain, thymosin alpha‑1 decreased up-regulation of IL-6 in inflamed skin and spinal cord.

    In plain wordsIn animals with inflammatory pain, thymosin alpha‑1 lowered the inflammation marker IL-6 in skin and spinal cord.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-6 in inflamed skin and spinal cord
    Study

    n: not reported in source

    CFA-induced inflammatory pain
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · intraperitonealAs given in this study.

    Source sentences

    Summary
    decreased the up-regulation of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) in inflamed skin and the spinal cord
  5. 05AnimalAnimal study (in vivo)Mechanism

    In animals with CFA-induced inflammation, thymosin alpha‑1 reversed strong microglial activation.

    In plain wordsIn animals with inflammation, thymosin alpha‑1 reversed the activation of microglia, immune cells of the nervous system.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCFA-induced microglial activation
    Study

    n: not reported in source

    CFA-induced inflammatory pain
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study.

    Source sentences

    Summary
    We found that CFA-induced peripheral inflammation evoked strong microglial activation, but the effect was reversed by Tα1.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In animals with CFA-induced inflammation, thymosin alpha‑1 reversed the up-regulation of VGLUT in the spinal cord.

    In plain wordsIn animals with inflammation, thymosin alpha‑1 reversed a rise in the transporter VGLUT in the spinal cord.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseVGLUT up-regulation in spinal cord
    Study

    n: not reported in source

    CFA-induced inflammatory pain
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study.

    Source sentences

    Summary
    Tα1 reversed the CFA-induced up-regulation of vesicular glutamate transporter (VGLUT) and down-regulated the vesicular γ-aminobutyric acid transporter (VGAT) in the spinal cord.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In animals with CFA-induced inflammation, thymosin alpha‑1 down-regulated VGAT in the spinal cord.

    In plain wordsIn animals with inflammation, thymosin alpha‑1 lowered the transporter VGAT in the spinal cord.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseVGAT expression in spinal cord
    Study

    n: not reported in source

    CFA-induced inflammatory pain
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study.

    Source sentences

    Summary
    down-regulated the vesicular γ-aminobutyric acid transporter (VGAT) in the spinal cord.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.